Original Article

A Retrospective Review of Clinical Experience with Daptomycin for a Variety of Wound Types in a Burn and Wound Care Facility

Authors: Bruce C. Friedman, MD, Luke Mendez-Vigo, PharmD, Joan Wilson, MSN, Mha, RN, Sara Yankelev, MS, MPH


Objective: Daptomycin is a novel antibiotic with activity against many Gram-positive organisms that has demonstrated efficacy in the management of skin and soft tissue infections (SSTIs). However, data regarding the use of daptomycin for the management of burn wound infections are lacking. We assessed the efficacy and safety of daptomycin in the treatment of complicated skin and soft tissue infections (cSSTIs), including burn wound infections.

Methods: We performed a retrospective review of patients receiving daptomycin for burn wound infections and other cSSTIs in a referral burn and wound treatment center.

Results: Our review revealed an overall success rate (microbiological cure + clinically improved) of 99.5%, with an overall success rate of 98.5% among burn patients, specifically. The overall success rate was 100% among patients in the three other diagnosis groups (cSSTIs, chronic wounds, and other infections). A success rate of 98% was noted among the subset of patients with wounds associated with bacteremia.

Conclusions: Our study suggests that daptomycin is a safe and effective agent for the management of burn wound infections, although further study is warranted to confirm these results.

Key Points

* Daptomycin is a safe and effective agent for the management of burn wound infections, although further study is warranted to confirm these results.

* Our findings suggest that daptomycin is a safe treatment option for this population, including those patients with elevated baseline creatine phosphokinase values.

* This study provides further support for the use of daptomycin for the treatment of a wide range of other types of complicated skin and soft tissue infections.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.


1. Eisenstein BI. Treatment challenges in the management of complicated skin and soft-tissue infections. Clin Microbiol Infect 2008;14(suppl 2):17–25.
2. Church D, Elsayed S, Reid O, et al. Burn wound infections. Clin Microbiol Rev 2006;19:403–434.
3. Sharma BR. Infection in patients with severe burns: causes and prevention thereof. Infect Dis Clin North Am 2007;21:745–759, ix.
4. Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis 2007;57:7–13.
5. Moran GJ, Krishnadasan A, Gorwitz RJ, et al; EMERGEncy ID Net Study Group. Methicillin-resistantS. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666–674.
6. Hersh AL, Chambers HF, Maselli JH, et al. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 2008;168:1585–1591.
7. Garau J. Management of cSSTIs: the role of daptomycin. Curr Med Res Opin 2006;22:2079–2087.
8. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 2005;6:283–295.
9. Cubist Pharmaceuticals, Inc. Cubicin® (daptomycin for injection) [Prescribing Information]. Lexington, Cubist Pharmaceuticals, Inc., 2008.
10. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673–1681.
11. Owens RC Jr, Lamp KC, Friedrich LV, et al. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. Am J Med 2007;120(10 suppl 1):S6–S12.
12. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005;55:240–245.
13. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureusN Engl J Med 2006;355:653–665.
14. Blanchet B, Jullien V, Vinsonneau C, et al. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 2008;47:635–654.
15. Mohr JF III, Ostrosky-Zeichner L, Wainright DJ, et al. Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother 2008;52:1891–1893.